Have questions? Contact Us
Recent Epidemiological Trends in Respiratory Syncytial Virus (RSV) Activity
Following the disruption of typical respiratory virus circulation patterns during the COVID-19 pandemic, the United States is currently experiencing an early and significant surge in Respiratory Syncytial Virus (RSV) activity for the 2025-2026 season. Epidemiological data from the CDC's RSV-NET and the National Respiratory and Enteric Virus Surveillance System (NREVSS) indicate a sharp increase in RSV detections and hospitalizations beginning in late summer and accelerating through October and November. This trajectory mirrors the early onset observed in the 2022-2023 season, suggesting a potential return to pre-pandemic seasonality, albeit with elevated intensity.
Recent surveillance reports highlight a concerning rise in RSV-associated hospitalization rates, particularly among infants aged <6 months and older adults aged ≥65 years. Data indicates that hospitalization rates in these vulnerable cohorts are currently tracking above the historical average for this time of year. The positivity rate for RSV PCR tests has also seen a rapid incline across multiple HHS regions, signaling widespread community transmission. This early surge underscores the critical need for timely administration of the new RSV vaccines for older adults and pregnant individuals, as well as the nirsevimab or clesrovimab monoclonal antibody options for infants. Beyfortus & Enflonsia are the trade names by Sanofi & Merck respectively. These RSV prevention options have impressive results to mitigate severe disease and alleviate strain on pediatric and adult healthcare systems. Find the AAP RSV specific recommendations here. Adult RSV vaccines are available as mResvia by Moderna, Arexvy by GSK and Abrysvo by Pfizer. The Pfizer RSV vaccine is the only RSV vaccine approved for use in pregnant woman. Find the CDC’s RSV specific recommendations for adults here. ACOG’s RSV recommendations for pregnant women can be found here.
As the general respiratory virus season gets underway, healthcare providers can gain access to essential vaccine discounts on RSV vaccines, RSV monoclonal antibody options, Flu vaccines, Pneumonia vaccines and COVID vaccines through Physician’s Buying Group PBG contracts. The PracticeWell team is here to find out more about a practice’s unique needs and help physicians decide which vaccine contracts would work best for their practice. Join PracticeWell PBG for free.